Gianluca Ferini1, Laura Molino2, Laura Bottalico3, Paolino De Lucia3, Francesco Garofalo3. 1. REM Radioterapia srl, Viagrande (CT), Italy. 2. Radiation Oncology Unit - Department of Biomedical, Dental Science and Morphological and Functional Images, University of Messina, Messina, Italy. 3. Malzoni Radiosurgery Center, Agropoli (SA), Italy.
Abstract
BACKGROUND: The aim of the study was to evaluate local control and toxicities of strongly hypofractionated electron beam radiotherapy (RT) in elderly and fragile patients with facial nonmelanoma skin cancer (NMSC). MATERIALS AND METHODS: We enrolled patients aged ≥ 65 years with facial NMSC, Karnofsky Performance Status (KPS) ≥ 40 and life expectancy ≥ 6 months, amenable neither to daily RT nor surgery. Radiotherapy consisted of 35 Gy, delivered with 6 MeV electron beam, in 5 fractions of 7 Gy/day twice a week (tw). Prescription isodoses were 100% for cT1-cT2 and 90% for cT3-cT4. Objective response was assessed clinically 4 and 8 weeks after the end of RT and then monitored every 6 months. Side effects were assessed according to the CTCAE scale. RESULTS: 12 patients of median age 89.5 years with a total of 23 NMSC cN0 achieved a median follow-up time of 6 months (range 1-10), with total treatment compliance. 10/12 patients had a 40 ≤ KPS < 70 and 2/12 a 70 ≤ KPS < 90. 5/12 patients had synchronous lesions. 22/23 lesions were classified as T1-T2 and had complete response (CR), 1/23 as T4 with partial response (PR). Within 4 weeks after the end of treatment, G1 toxicity was reported for 12/23 lesions, G2 for 8/23, G3 for 3/23, G4 for 0/23, all disappeared 8 weeks later, with or without topical therapy. After last follow-up (1 June 2020) 1/12 patients died with PR from senile marasmus, 11/12 are alive with CR and widely tolerated toxicities. CONCLUSIONS: Extreme hypofractionation of radiotherapy dose for facial NMSC is effective, safe and suitable for elderly patients.
BACKGROUND: The aim of the study was to evaluate local control and toxicities of strongly hypofractionated electron beam radiotherapy (RT) in elderly and fragile patients with facial nonmelanoma skin cancer (NMSC). MATERIALS AND METHODS: We enrolled patients aged ≥ 65 years with facial NMSC, Karnofsky Performance Status (KPS) ≥ 40 and life expectancy ≥ 6 months, amenable neither to daily RT nor surgery. Radiotherapy consisted of 35 Gy, delivered with 6 MeV electron beam, in 5 fractions of 7 Gy/day twice a week (tw). Prescription isodoses were 100% for cT1-cT2 and 90% for cT3-cT4. Objective response was assessed clinically 4 and 8 weeks after the end of RT and then monitored every 6 months. Side effects were assessed according to the CTCAE scale. RESULTS: 12 patients of median age 89.5 years with a total of 23 NMSC cN0 achieved a median follow-up time of 6 months (range 1-10), with total treatment compliance. 10/12 patients had a 40 ≤ KPS < 70 and 2/12 a 70 ≤ KPS < 90. 5/12 patients had synchronous lesions. 22/23 lesions were classified as T1-T2 and had complete response (CR), 1/23 as T4 with partial response (PR). Within 4 weeks after the end of treatment, G1 toxicity was reported for 12/23 lesions, G2 for 8/23, G3 for 3/23, G4 for 0/23, all disappeared 8 weeks later, with or without topical therapy. After last follow-up (1 June 2020) 1/12 patients died with PR from senile marasmus, 11/12 are alive with CR and widely tolerated toxicities. CONCLUSIONS: Extreme hypofractionation of radiotherapy dose for facial NMSC is effective, safe and suitable for elderly patients.
Authors: Armand B Cognetta; Brett M Howard; Henry P Heaton; Earl R Stoddard; Hyokyoung Grace Hong; W Harris Green Journal: J Am Acad Dermatol Date: 2012-07-19 Impact factor: 11.527
Authors: Nicholas G Zaorsky; Charles T Lee; Eddie Zhang; Scott W Keith; Thomas J Galloway Journal: Radiother Oncol Date: 2017-08-23 Impact factor: 6.280
Authors: May N Tsao; Richard W Tsang; Fei Fei Liu; Tony Panzarella; Lorne Rotstein Journal: Int J Radiat Oncol Biol Phys Date: 2002-03-15 Impact factor: 7.038
Authors: Paolo Palmisciano; Gianluca Ferini; Christian Ogasawara; Waseem Wahood; Othman Bin Alamer; Aditya D Gupta; Gianluca Scalia; Alexandra M G Larsen; Kenny Yu; Giuseppe E Umana; Aaron A Cohen-Gadol; Tarek Y El Ahmadieh; Ali S Haider Journal: Cancers (Basel) Date: 2021-12-24 Impact factor: 6.639